Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma.

DelveInsight's "Paranasal Sinus Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...

DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...

NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...